MDxHealth SA (MDXH)
MDXH trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1872529/000121390026039540/0001213900-26-039540-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MDXH on Nasdaq |
| Sector | Health Care |
| Industry | Medical Specialities |
| Country | Belgium |
| IPO year | 2021 |
| SEC CIK | 0001872529 |
| SEC industry code | Services-Medical Laboratories |
| Incorporated in | Belgium |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $107.9M |
| Net income | -$33.5M |
| Operating income | -$14.4M |
| Net margin | -31.1% |
| Operating margin | -13.4% |
| Revenue growth | +19.8% |
| Cash | $29.0M |
| Total assets | $148.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As discussed in Note 2.3 to the consolidated financial statements, the Company has suffered recurring losses from operations and expects to incur significant cash outflows for at least the next twelve months that raise substantial doubt about its ability to continue as a going concern." | 20-F 2026-04-03 |
| Cash and burn | $29.0M cash; operating cash flow -$547K a quarter. | Report 2025-12-31 |
| Shares outstanding | 51,364,520 (2025-12-31); 49,497,334 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO Bedrijfsrevisoren - BDO Réviseurs d'Entreprises, Zaventem, Belgium | PCAOB Form AP 2026-04-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $991K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 95,417,377 shares at the 2026-11-13 price; the latest SEC cover count is 51,364,520 as of 2025-12-31. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $107.9M | -$33.5M | -$2.2M | $29.0M | $76.2M | $107.9M | 20-F 2026-04-03 |
| FY 2024 2024-12-31 | $90.0M | -$38.1M | -$18.5M | $46.8M | $51.0M | $90.0M | 20-F 2026-04-03 |
| FY 2023 2023-12-31 | $70.2M | -$43.1M | -$21.5M | $22.4M | $35.6M | $70.2M | 20-F 2026-04-03 |
| FY 2022 2022-12-31 | $37.1M | -$44.0M | -$34.1M | $15.5M | $34.9M | $37.1M | 20-F 2025-03-31 |
| FY 2021 2021-12-31 | $22.2M | -$29.0M | -$22.5M | $58.5M | No debt tags | $22.2M | 20-F 2024-04-30 |
| FY 2020 2020-12-31 | $18.5M | -$28.7M | -$20.2M | $16.0M | No debt tags | $18.5M | 20-F 2023-04-25 |
| FY 2019 2019-12-31 | $11.8M | -$43.1M | -$22.3M | Not filed | No debt tags | $11.8M | 20-F 2022-04-25 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-08-13 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-04-03 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 185 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.3% |
| 1 month | -78.2% |
| 3 months | -68.8% |
| Year to date | -96.0% |
| 1 year | -96.4% |
| From 52-week high | -96.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical Specialities
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMS | American Shared Hospital Services | $1.07 | -0.93% | $7.1M |
| ACH | Accendra Health Inc. | $0.0857 | -35.08% | $6.6M |
| ACON | Aclarion Inc. | $1.39 | -12.58% | $4.0M |
| ADVB | Advanced Biomed Inc. | $2.22 | -12.25% | $3.7M |
| SERA | Sera Prognostics Inc. | $1.94 | -3.48% | $77.2M |
| BGLC | BioNexus Gene Lab Corp | $0.8200 | -0.12% | $2.4M |
| XGN | Exagen Inc. | $3.77 | -8.72% | $96.2M |
| BDSX | Biodesix Inc. | $9.00 | -8.91% | $99.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier